[{"orgOrder":0,"company":"Freya Pharma","sponsor":"Emotional Brain BV","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Freya Pharma \/ Emotional Brain BV","highestDevelopmentStatusID":"8","companyTruncated":"Freya Pharma \/ Emotional Brain BV"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE-5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Delayed Immediate Release","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Freya Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil that used for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD...

                          Brand Name : Lybrido

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 19, 2023

                          Lead Product(s) : Sildenafil Citrate,Testosterone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil. It increases central sexual motivation and physiological sexual responses.

                          Brand Name : Lybrido

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 09, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Lybrido (sildenafil) intends to increase central sexual motivation and physiological sexual responses. It consists of a novel combination tablet containing a testosterone coating for sublingual administration and an inner-core component made of the PDE-5...

                          Brand Name : Lybrido

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 02, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Lybrido (sildenafil) is a unique therapeutic concept, both by its combination of testosterone and sildenafil, as well as by its dual route, dual release, fixed dose system, and as such achieving the optimal synergy of both active ingredients.

                          Brand Name : Lybrido

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 25, 2022

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Lybrido (sildenafil) increases central sexual motivation and physiological sexual responses, such as swelling of vaginal erectile tissue and lubrication.

                          Brand Name : Lybrido

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 28, 2022

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The new funding will be used to carry out a pivotal phase 3 trial with its therapy Lybrido in 516 patients across Europe. Lybrido showed clinical relevance and statistical significance in a phase 2b clinical trial, clearly meeting the primary endpoints.

                          Brand Name : Lybrido

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 29, 2022

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $8.5 million

                          Deal Type : Financing

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Freya Pharma has been established to further advance two compounds for the FSIAD-disorder, Lybrydo and Lybrydos, that have shown clinical and statistical relevance in an earlier phase 2b clinical trial, clearly meeting the primary endpoints.

                          Brand Name : Lybrido

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 17, 2021

                          Lead Product(s) : Sildenafil Citrate,Testosterone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase II

                          Sponsor : Emotional Brain BV

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank